AXIMA

Characterization of Salmonella typhimurium membrane proteins separated by 2D gels

The AXIMA-CFR high performance MALDI-TOF with curved field reflectron, was used to analyze a membrane fraction of S. *typhimurium* proteins resolved by 2D gel electrophoresis.

The rapid acquisition of high quality seamless PSD data allowed unequivocal identification and characterization of co-migrating proteins which upon tryptic digestion had generated peptides of a similar nominal mass.



Introduction

Matrix-assisted laser desorption ionization time-offlight mass spectrometry (MALDI)⁽¹⁾ is now widely used in the field of proteomics. Key requirements in this area are: high sensitivity, high resolution and mass accuracy and rapid analysis for high throughput. Both precursor and product ion (in the form of PSD) data can be used for the positive identification of proteins. Until now, with conventional reflectron designs $^{(2)}$, the acquisition of post-source decay spectra (PSD) has been quite time consuming requiring multiple analyses at varied reflectron voltages and stitching together of the resulting spectra. The incorporation of the curved-field reflectron⁽³⁾ into MALDI TOF instruments significantly increased the speed and sensitivity of the PSD analysis by enabling the acquisition of a fully focused PSD spectrum in a single analysis: seamless PSD (sPSD). All the advantages of the curved-field reflectron have now been integrated into a high resolution/high sensitivity MALDI TOF instrument⁽⁴⁾, the AXIMA-CFR.

Proteomics provides a powerful tool for exploring protein levels at the whole cell level. It can be used to determine the response of bacteria to their environment and as such, provides a fingerprint of the status of the cell at a given point in time. This strategy can be used to examine membrane preparations of bacteria for the presence of surface proteins and transport proteins. The AXIMA-CFR was used to analyze a membrane fraction of *Salmonella typhimurium* proteins which had been resolved by 2D gel electrophoresis (Figure 1).

Method

Protein spots were treated by in-gel digestion using trypsin, the peptides extracted and then desalted prior to MALDI sample preparation. The curved-field reflectron MALDI TOF mass spectrometer (AXIMA-CFR) was used, which comprises: UV nitrogen laser (337 nm), near ultra high vacuum system with novel laser beam focusing mechanism for increased ion extraction efficiency and increased sensitivity, an integrated 1 GHz transient recorder, optimized ion optics for high resolution and accuracy, a high resolution ion gate for parent ion selection for sPSD analyses, and a microplate-type target.

All the MALDI analyses, for each sample, were performed on a single 0.5 μl aliquot using the dried droplet sample loading technique with α -cyano-4-hydroxy cinnamic acid matrix saturated in 1:1 acetonitrile/0.1% TFA.

Database searches were performed using the Mascot[™] search engine (Matrix Science).



Results

The performance of the instrument in relation to in-gel digest of 2D gel separated proteins is illustrated with an example from *Salmonella typhimurium* (protein spot 3). The following observations were made:-

1 A 40 kDa protein (Coomassie Blue stained) digested with trypsin generated a complex series of signals in the mass range 800 to 3500 Da (Figure 2). Isotopic resolution was obtained across the whole mass range at a single pulsed extraction value. This enabled the monoisotopic peak from each signal to be used in the Mascot[™] peptide mass fingerprint search engine and resulted in the primary identity of the protein to be outer membrane protein A (OMP A) from Salmonella typhimurium (Table 1).

Access										
	ii on	Rann	Score	Bendription.						
	140	27566	66	COTER HEREGAME PROTEIN & PRECURSOR COUTER HEREGARE PROTEIN.						
	141	37718	87	CUTER MENDO.	ANE PROT	RIN A	PRECUS	ODE COUTER MANREARE PROTEIN		
at 1744	4575	44130	62	myshable imperson - Boolshaway samplane souther and 17						
111111	1122	24126	40	provide an entropy of a contract of the second of the second seco						
- SHIARS	12425	00110	40	toris and and stories a toris different for the line of the						
- BALLER	1122	10114		COLUMN DESIGN	the proc	A test	- adding	ALL AND AN AND AND AND AND AND AND AND AND		
911122	1.95	07176	47	COLES HERESARS MOLEIN Y AMELONOUS COLLES HERBEVER ABOLEIN						
481211	10.013	37248	44	(VA134548)	ruter as	NOT MILE	banes.	In A Inscherzenza colij		
- MAR728	4465	65757	40	(AB000974) ATP-dependent flp provesow sobeauty Divisils for						
· 181232	10.06.0	16207	43	prepilim - Morasella hovis						
- sil124	2721	42150	42	Chain A, Elongation Factor Complex If-TuEF-Ts From Encheri-						
- 951332	245	\$7075	41	DECA DEGTEIN						
011467	19921	40155	41	Chain A, Intact Elongation Factor From E.Coli						
ert 111	212	41256	41	BLONGATION FACTOR TU (MF-TU)						
******	281	43784	41	BOUNDATION REPTOR TO 199-901 JB-405						
	110	43224		REARING ANTICE IN TRA-INI (1-41)						
- 943.743	LAT.	10000		translation elongation factor EF-TH.A - Salaonalla typhiaus						
011338	13.28	47256		1110031012001	elonget.	A DOCT	cor E	COLUMN - ESCHEFICILE COLL		
931116	2823	107087	41	ALMON TRICH	SEC ACID	a stos	INTERST	LA PROTEIN DOAR		
1011675	1.72.2	37348	41	(V7738038) 1	pessible	sober	MARSH	otide spinsrass/dehydratas-		
411622	5.188	21949	41	STP-BINDING	PROTEIN	COPA				
st1697	6224	107371	40	(AF116191) 1	delin (D	acillu	1 12. 1	HE3-6061		
Observ.	and set	Hr (mgt.)	A PERCURS Br(cale)	Delta	Start.	End	N 22E)	Peptide		
872.1	09	871,07	971.51	-0.44	222 -	229	1	RVEI EVR.		
915.	20	914.19	914.52	-0.33	95 -	103	0	AGUUGLTAR		
1092.3	19	1062.28	1062.54	-0.96	223 -	291	0	SD/TLINPAR		
1187.	27	1156.26	1156.89	-0.33	322 -	332	Ď	AALTDCLASDE		
12.9.9	26	1292.26	1222.63	-0.92	110 -	124	1	LOOKVARADITE		
1764	14	1262.36	1262.07	-0.30	2.56 -	247		DODINIL CETOD		
1001	15	1360.35	1360 /7	-0.05	2.08	200		TOSTAVENCLARE		
1400	10	1460.25	1440.65	-0.00	198 -			A CONTRACTOR OF A CONTRACT OF		
1470.1	23	1467.70	1967.70	9.02	02 -		1	HYDRODUINGAIN		
1600.	10	1807.30	1667.01	-0.43	104 -	11.2	D	LOTFITUEDFTTR		
2302.1	20	2301.29	2362.20	-0.91	195 -	21.7	0	LOOGRAVEAN SYSTEM LAGIN		
r. <u>1111</u>	12142	Xante. 277	10 5	. 17	-					
E. MILL	EPLAN BHD FAR	Name . 277	A PERCURS	OR COUTER MS	THE PARK	PROTECT	N III)			
Cheere	EPLAT HEREAD	Manuel 277 1 SPOTEIN Martengel 1	A PERCENS Metcale1	08 COUTER HS Belta	Start	End	N II)	Peptide		
2. 11110 00723 20 00ser# 872.1	EPLAN MERAN	Xanis. 277 11 2907818 Hrimgt1 871,07	A PERCENS Metcale1 871.51	. 17 201 (007111 M Belta -0.44	Blart 334 -	Ead 340	Miss 1	Fegelide EVIIIWE		
2. <u>1111</u> 00783 M 00583 M 00587 M 872.1 915.1	12142 20142 20142 20142	Xanis. 277 II 2907ELN Hrimgt.1 871.07 914.19	10 Sours A SECORS Metcale 871.51 914.52	- 17 208 (007188 M9 9e814a -0.44 -0.33	81 944 81 art 334 - 95 -	5007511 End 300 103	MLau L D	Peptide DVEIEWE AQUVQLTER		
2. <u>mills</u> 00783 20 872.1 915.1 1027.3	22142 2005 Fail 08 20 27	Manue, 277 II 2907ELN Hriengt1 871,07 914,19 1926,26	10 Research A PERCORN Metcale 871.81 914.52 1026.88	. 57 505 (00755 MS -0.44 -0.33 -0.32	Start 334 - 95 - 294 -	Fad 340 103 303	I I I I I I I I I I I I I I I I I I I	Peptide DVEISVR AQUUQLTAR GIPADRISAD		
 <u>milli</u> <u>milli</u> Maserro 872.1 <u>915.1</u> <u>1027.1</u> <u>1023.1</u> 	29143 and Fall ed 08 20 27 19	Name . 277 H 2907KIN Hr (mapt.) 871.07 914.19 1025.25 1002.10	10 None A PERCURS Metcale1 871.51 914.52 1026.58 1062.54	. 57 508 (00788 HS -0.44 -0.33 -0.32 -0.32	Start 334 - 95 - 294 - 224 -	End 340 103 203 203	N II) NLes 1 0 1 0	Peptade DVEISVX AQUYQLIAK GIPADKIBAD SDVIJERAD SDVIJERAD		
E. <u>milli</u> 007E3 M Baser W 87Z. 915. 1027. 1027. 1083. 1083.	29143 2005 20 27 19 27	Manuel, 277 H PROTEIN Hertengel 1 871, 07 914, 19 1026, 26 1052, 10 1186, 26	10 State A F550085 Mr4cale 971.51 914.52 1026.58 1062.54 1156.55	. 57 208 (007158 MS -0.44 -0.32 -0.32 -0.35 -0.55	Start 334 - 95 - 294 - 224 - 353 -	Ead 340 103 202 333	U II) I I I 0 0	Perfilde DVEINVE AQUPULTRE GIRADEIRAR SDULREPER ALLICCLARPE		
E. <u>milli</u> 007E3 M Boser w 87Z. 915. 1027. 1083. 1083. 1293.	12143 200 Faab 20 27 19 27 26	Manuel, 077 H SPOTKIN Hrtengel 1 871,07 914,19 1926,26 1962,19 1966,26 1962,26	10 State A PERCORE Metcale 971.51 914.52 1026.58 1062.54 1166.59 1202.63	4. 27 203 (OUTER M3 -0.44 -0.33 -0.32 -0.32 -0.53 -0.53 -0.29	8000000 81000 95 - 294 - 294 - 294 - 294 - 110 -	PROTECT End 340 103 203 232 353 126	1 11 9 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide pvezeve AQUVLTER CTRAPTERA SDVLPHPER AALT-CLAPPE LOREWINGTE		
 milii cortes m 872.1 916.1 1027.1 1023.1 1223.1 1241.1 	22143 200 Faab 20 27 19 27 26 26	Manue, 277 01 9907818 Mr (resp): 1 571,07 914,19 1026,26 1062,10 11062,26 11062,26 11062,26 11062,26	10 Sease A \$550085 Metcaler 871.51 \$14.52 1026.58 1062.54 1156.89 1232.43 1250.01	4. 27 208 (007188 M -0.44 -0.33 -0.32 -0.35 -0.53 -0.53 -0.57	Start Start 95 - 294 - 224 - 224 - 343 - 110 - 104 -	PROTECT End 340 103 303 232 353 128 117	111 8 10 1 1 1 0 1 0 1 0 1 0	Peptide DVEISUR AQUIVATAR GIPACHIEAN SURJANNA ALITCLARDE LOUGIVALADE LOUGIVALADE LOUGIVALADE		
F. MITE 7. OUTES 7. GLOUP 8 72. 915. 1027. 1083. 1083. 1233. 1335. 1335.	12142 HDS FAAR 08 20 27 19 27 19 27 26 19 41	Name. 277 19 3937818 Mrimgtl 571.07 914.19 1926.26 1962.10 1166.26 1952.26 1952.26 1952.40	10 State A FESCORS Medeale1 871.51 914.52 1026.58 1002.54 1156.59 1210.69 1200.94	4. 27 308 (OUTER MS -0.44 -0.33 -0.32 -0.36 -0.53 -0.59	81 0.448 3 81 art 334 - 95 - 234 - 234 - 234 - 343 - 110 - 104 - 293 -	PROTECT Ead 340 103 303 232 333 128 117 294	111 8 10 1 1 1 0 1 0 1 0 1 0	Peptide DVSIEWS AQUIVATER CTARFCEAS SULTENESE AALDECLAPPE LOUDENADTR LOUDENADTR LOUDENADTR ANDRESTIGLENETS		
F. <u>milli</u> OUTES R. Bacer w 872.1 915.1 1027. 1002. 1002. 1223. 1041. 1003.	19143 205 20 27 19 27 26 29 41 00	Name. 277 10 2007818 Herman. 571.07 914.19 1002.26 1002.10 1002.26 1002.26 1002.26 1002.40 2002.40	10 Score A PERCORS Medualet 871.81 914.52 1026.88 1082.54 1186.89 1282.60 1610.00 1202.90	4. 27 2011 (OUTER 122 -0.24 -0.23 -0.32 -0.32 -0.26 -0.29 0.57 -0.39 0.57 -0.39	Start Start 354 - 95 - 254 - 224 - 343 - 110 - 104 - 223 -	PROTEIN Ead 340 103 303 232 333 128 117 299	11 9 1 0 1 0 1 0 1 1 1	Peptide DVIIINT AQUIVITAR DIVINAR DIVINAR ALITCLARD ALITCLARD LOBOWIADIR LOBOWIADIR LOBOWIADIR AQUIVILISEDIAR AQUIVILISEDIAR		
r. <u>milli</u> 007123 R 872.1 915.1 1007. 1003.1 1203.1 1203.1 1203.2 2672.1	19143 and 584 20 20 27 19 27 26 59 41 02	Xmms. 277 11 29075139 Hr (magt.) 571.07 914.19 1026.26 1062.10 1186.26 1292.26 1292.26 1292.40 2671.02	10 State A PERCENT Wetanket 974.52 1026.58 1082.54 1186.89 1292.69 1292.99 1292.99 1292.99	1. 27 2021 (207782, 82 -0. 44 -0. 33 -0. 32 -0. 33 -0. 33 -0. 33 -0. 26 0. 57 -0. 29 0. 73	844 5444 844 95 - 294 - 224 - 343 - 110 - 104 - 293 - 257 -	PROTEIN 540 103 303 202 353 128 117 299 201	110 1 0 1 0 0 1 0 1 0 1 1	Peptide DVDING DVDING DVDING DVDING DVDING NAUTOLAPS AND PEPS AND PEPS AND PEPS AND PEPS AND PEPS AND PEPS AND PEPS DVDING DVDI		
 milit 	17143 2007 20 20 27 19 27 26 19 41 02	Name. 277 R 2907E19 Hrimgt1 571.07 914.19 1026.26 1092.19 1192.26 1092.26 1092.40 2671.02	10 3.445 A 3530000 Medeale1 871.51 914.52 1026.58 1026.52 1026.58 1026.59 1000000000000000000000000000000000000	6. 27 200 00715.8.20 8421a -0.44 -0.22 -0.24 -0.37 -0.24 -0.53 -0.24 0.77 -0.50 0.73	Start Start 95 - 294 - 224 - 343 - 144 - 104 - 292 - 257 -	790750 End 3907 103 303 232 333 128 129 291	9 11) Hies J D J D J D J D J J J J	Peptide Eventer Augurgutak Gerankteras Evelsene Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer Langeverlaufer		
 mili (00783 % 000783 % 000000 % 015.1 1027.1 102	17143 27143 20 27 26 29 41 02 311113 KATIO	Name. 277 8 3907EIN Briangti 571.07 914.19 1526.26 1526.26 1522.10 1526.26 1522.26 1522.40 2671.02 5211 Manuel 5 FACTOR 17	10 Bears A F500005 Mr 50005 871.51 871.51 1082.54 1082.54 1082.54 1082.54 1082.96 1082.96 2670.29 2670.29	 67 608 (00718.8.89) 98.811.8 -0.44 -0.23 -0.24 -0.31 -0.26 -0.28 0.73 -0.29 0.73 Score: 42 	899 DANT 11art 254 - 254 - 254 - 254 - 110 - 104 - 292 - 257 -	PROTECT Field 340 103 303 232 353 128 117 295 201	9 11) Mise 1 0 1 0 1 0 1 1	Peptide Evilian Augustation Eleventer Augustation Evilianter Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer Longevaluer		
 mili outes 3 messa 4 pii i027. pii i027. i028. <lii028.< li=""></lii028.<>	17143 275 FAS 20 27 19 27 26 99 41 02 02 02 02 02 02 02 02 02 02	Name. 277 H 9907ELW Hr (mag.t.) 571.07 914.19 1092.26 1092.10 1092.10 1092.40 2671.02 2711 Name: FACTOR 77 Netempt	10 Boars A FERCIDE Medealer 871.53 874.52 1026.58 1082.54 1282.63 1282.63 1282.63 1282.90 2670.29 : 40256 ft 1827-TU 5 Meteo	 	<pre>####################################</pre>	PROTECT Field 340 103 303 232 353 128 127 295 291	8 11) Hies J D D D 1 D 1 1 1 N	Peptide Proling Proling Proling Provide Pro		
 mili course m course m course m str. str.<	12142 275 FAU 20 27 19 27 26 59 41 02 311113 Garrod 627, 25	Name. 277 H 2937818 Bringti 571,07 914,19 1526,28 1586,28 1586,28 1586,28 1582,18 1586,24 1592,18 1592,18 1592,40 2671,02 Fill Manue FACTOR T Noticegel 2007,50	10 State A SECOND Welease STL 51 971, 51 974, 52 1026, 58 1022, 63 1022, 63 1022, 63 1022, 63 1022, 63 1022, 63 1022, 63 1022, 98 2070, 29 2070, 29 2070, 29 2070, 29 2070, 29 2070, 29 2070, 29 2070, 29 2070, 20 20, 20, 20 2	 	<pre>####################################</pre>	Fact 510 540 103 303 233 128 117 299 201	8 112) Hier 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide EVELIAR AQUIVITAR STALENTER STALENTER STALENTER LOTEVINGENTE L		
 E. <u>mili</u> COUTES E COLOUTES E COLOUTES E PIS. PIS.	12142 2015 Fad 20 27 19 27 26 29 41 02 311113 6647100 677.25 27.25	Names. 077 1 2907E19 167:0021 167:0021 162:02 162	10 Bases A FERCURE NETALS STL 51 924.82 1026.84 1026.84 1026.94 1026.94 1026.94 2670.29 2670.29 2670.29 3 decent 0 decen	. 27 308 (000728 M3 -0.32 -	<pre>####################################</pre>	Fact 510 Fact 540 103 303 202 303 128 117 295 201 4 8 - 1 -	8 11) MLess J D D D D 1 D 1 1 1 MLES N 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide SYSINE SYSIN		
 mili more a more a	12142 275 Fad 20 27 19 27 26 29 41 02 311113 6G2100 607.25 27,25 27,27 14,27	Emen. 277 18 2907ELN Refeatl 571.07 914.19 1052.26 1052.26 1052.26 1052.26 1052.9 10	10 Sears A process Bitecalar 914,52 1026,50 1026,54 1026,54 1026,54 1026,54 1026,54 1026,54 1026,54 1026,54 1026,54 1026,55 1026,55 5 1026,55 5 1026,5 1026,5 100,5 10,5 1	 	**************************************	FBOTED End 347 103 202 353 128 117 299 201 4 8 - 1 - 1 - 5 -	8 11) Miss J J J D J D J D J D J D J D D J D D J D D D J D D D D D D D D D D D D D	Paptian STRING ACTURATE ACTURATE ACTINATES ETRAFTERS EVENTERS ACTINATION ACTINATIO		
 mili corres a corres a corres a srz. pis. 1002. 1002.	12142 249 Fad 00 27 19 27 26 19 41 02 311111 02 311111 02 10 10 27 14 26 19 10 27 16 27 16 27 18 27 19 26 27 19 26 27 19 26 27 19 26 27 19 26 27 19 26 27 19 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 26 27 26 26 26 27 26 26 26 26 26 26 26 26 26 26	Emes. 277 12 2007ELW 15 1007ELW 15 1007 15 107 15	(10 Buars A FEDURE Bridealer 871,81 914,82 1026,88 1082,64 1082,64 1082,98 2070,29 20,29 20,20,29 20,2	. 27 308 (30728 A2 -0.32 -0.23 -0	<pre>### DANE : #tart 354 - 254 - 224 - 343 - 104 - 223 - 257 - 258 - 257 - 25</pre>	Field State Field Self 103 303 202 333 128 117 299 201 4 8 - 1 - 8 - 1 - 8 - 1 - 8 - 1 - 8 - 1 -	8 112) MLess J D J D 1 D 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide PVEINT PVEINT CITALNE CITALE DULINERS AASTICLASSE LOTENTISELOUTE LOTENTISELOUTE LOTENTISELOUTE LOTENTISELOUTE TOUTVULOYTDELOGIATEQUEE Res Peptide 0 ACTUALSE 0 ACT		
 mili corres corres s s	12142 195 Fail 10 27 10 27 26 10 27 26 10 27 26 10 27 26 10 27 26 10 27 26 10 27 26 10 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 27 27 27 27 27 27 27 27	Hanne. 277 (J 2007RIN Martempth 571.07 944.19 1400,28 1502,20 1502,20	10 Bears A PERCURE NE4calar 914,52 914,52 914,52 1282,54 1282,54 1282,54 1282,54 1282,54 1282,54 1282,55 1282,54 1282,55 12	- 57 050 (00759 50 - 500 050 (00759 50 - 50 -0.23 -0.33 -0.33 -0.5 -0.3 -0.5 -0	**************************************	Fact 512 Field 540 103 2040 103 2040 103 2040 103 2040 103 2040 103 2040 103 2040 103 2040 103 104 104 104 104 104 104 104 104 104 104	8 11) Miss 1 0 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Papilak DVIIIVK DVIIIVK DVIIIVK DVIIIVK DVIIIVK DVIIIVK DVIIIVK DVIIIVK DVIVVIIISEDIALK LOSEVVUIISEDIALK LOSEVVUIISEDIALK DVIVVIIISEDIALK DVIVVIIISEDIALK DVIIIVK DVIVVIIISEDIALK DVIIIVK DVIVVIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIIISEDIALK DVIVVIIII		
 mili cortes a Bacero Bracero Braz Braz<td>12142 249 Fad 08 00 27 19 27 19 41 02 02 02 02 02 02 02 02 02 02</td><td>Emes. 077 (1 2007LIN Brienghi 1076.26 1082.10 1086.26 1082.10 1086.26 1082.26 1082.40 2671.02 2671.02 2671.02 2671.02 2672.0 1082.40 2673.02 1082.40 2673.02 1082.5 1082.5 1086.24 100</td><td>(10 Shores A FSDUTED Bridealer 971, 81 914, 82 1092, 84 1092, 84 1092, 84 1092, 94 1292, 43 1292, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1</td><td>- 37 000 (000720 M3 -0.44 -0.44 -0.32 -0.35 -0.55 -0.57 -0.59 0.73 0.75 0</td><td>Start 374 - 294 - 294 - 294 - 110 - 297 -</td><td>4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5</td><td>8 11) Miss 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Peptide FVELINE AUGUVALEXE GIVENERSE ALTECLEDE LOBENERSE LOB</td>	12142 249 Fad 08 00 27 19 27 19 41 02 02 02 02 02 02 02 02 02 02	Emes. 077 (1 2007LIN Brienghi 1076.26 1082.10 1086.26 1082.10 1086.26 1082.26 1082.40 2671.02 2671.02 2671.02 2671.02 2672.0 1082.40 2673.02 1082.40 2673.02 1082.5 1082.5 1086.24 100	(10 Shores A FSDUTED Bridealer 971, 81 914, 82 1092, 84 1092, 84 1092, 84 1092, 94 1292, 43 1292, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1294, 43 1	- 37 000 (000720 M3 -0.44 -0.44 -0.32 -0.35 -0.55 -0.57 -0.59 0.73 0.75 0	Start 374 - 294 - 294 - 294 - 110 - 297 -	4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5	8 11) Miss 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide FVELINE AUGUVALEXE GIVENERSE ALTECLEDE LOBENERSE LOB		
 milli cortes a Cheere 877. Sis. 1027. 1022. 1223. 123. 123. 123. 123. 123. 123. 123. 124. 124. 125. 126. 126.	12142 1919 Fail 10 20 27 26 19 26 19 27 26 19 26 10 27 26 27 27 24 27 27 24 27 26 27 27 24 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 27 26 27 27 27 27 27 27 27 27 27 27	Masse. 277 U SOUTLIN Martempth 571.07 P34.19 571.07 P34.20 1802.26 1802.26 1202.26 1202.26 2671.02 2671.02 594.20 1802.40 2671.02 2011.00 594.20 1802.40 2671.02 2112.12 1006.2 1212.2.2 1213.2 1212.2.2 121.7.2 122.2.2 121.7.2 122.2.2 121.7.2 122.2.2 121.7.2 122.2.2 121.7.2 122.5 122.5 122.5 122.5	10 Shores A FBDUNK Mirdealer Wirdealer Wirdealer 1012 Size 1026 Size 1026 Size 1026 Size 1026 Size 1202 Size	. 17 DOI (0775) 50 -0.43 -0.44 -0.43 -0.44 -0.43 -0.44 -0.43 -0.44 -0	Start Start 334 - 294 - 294 - 294 - 294 - 292 - 294 - 295 - 29	FBOTHER Find 3460 103 303 232 3533 128 147 299 201 4 8 - 1 - 8 - 1 - 8 - 6 - 0 - 0 -	8 11) 1 0 1 0 1 0 1 0 1 0 1 0 1 1 1 1	Peptide SYSINX SYSIN		
 milli 001783 8 001783 8 011783 8 01183 1 1002. 1003. 1003.<td>12143 175 Fail 16 10 17 18 17 18 19 19 19 19 19 10 10 10 10 10 10 10 10 10 10</td><td>Numer. OPT 10 FORTELY Mariangell STL.07 914.19 STL.07 914.20 STL.07 1006.26 STL.07 1211 Manus 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.22 STL.07 1225.22 STL.02 1225.23 STL.02 1225.24 STL.02 1225.25 STL.02 1225.24 STL.02 1225.24 STL.02</td><td>10 Passe A FSDCURE A FSDCURE 871,81 914,82 1026,80 1026,90</td><td>. 17 DOI (UTTER H -0.44 -0.43 -0.43 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.43 -0.43 -0.4</td><td>Start 334 - 334 - 234 - 234 - 110 - 222 - 257 -</td><td>FBOTED Find 3987 103 303 232 353 123 235 242 353 127 295 201 4 2 2 2 1 7 2 2 5 2 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2</td><td>8 115) 16.00 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Peptide FVELINE AUGUVLEAR GTRANETAR SPULSEN ALTECLASSE LOTSTIGLENTE LOTSTIGLENTE LOTSTIGLENTE LOTSTIGLENTE AUGUVLENTE SEGILAR 0 RELLAR 0 RELLAR 0 AGENUTULE 0 ALTECLASSE 0 ALTECLASSE 0 ALTECLASSE 0 GTRANELSE 0 GTRANELSE 1 ETENSICTORIESE</td>	12143 175 Fail 16 10 17 18 17 18 19 19 19 19 19 10 10 10 10 10 10 10 10 10 10	Numer. OPT 10 FORTELY Mariangell STL.07 914.19 STL.07 914.20 STL.07 1006.26 STL.07 1211 Manus 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.21 STL.07 1225.22 STL.07 1225.22 STL.07 1225.22 STL.02 1225.23 STL.02 1225.24 STL.02 1225.25 STL.02 1225.24 STL.02 1225.24 STL.02	10 Passe A FSDCURE A FSDCURE 871,81 914,82 1026,80 1026,90	. 17 DOI (UTTER H -0.44 -0.43 -0.43 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.33 -0.43 -0.43 -0.4	Start 334 - 334 - 234 - 234 - 110 - 222 - 257 -	FBOTED Find 3987 103 303 232 353 123 235 242 353 127 295 201 4 2 2 2 1 7 2 2 5 2 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2	8 115) 16.00 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Peptide FVELINE AUGUVLEAR GTRANETAR SPULSEN ALTECLASSE LOTSTIGLENTE LOTSTIGLENTE LOTSTIGLENTE LOTSTIGLENTE AUGUVLENTE SEGILAR 0 RELLAR 0 RELLAR 0 AGENUTULE 0 ALTECLASSE 0 ALTECLASSE 0 ALTECLASSE 0 GTRANELSE 0 GTRANELSE 1 ETENSICTORIESE		

Figure 1. 2D Gel of the membrane fraction of Salmonella typhimurium proteins. Spots identified by MS analysis: 1. OMP D (outer membrane protein D); 2. FliC (phase-I Flagellin); 3. OMP A and EF-Tu (Outer Membrane Protein A precursor and Elongation Factor-Tu)

> Table 1. Mascot[™] database search results

- 2 Fourteen sPSD spectra were generated for twelve of the signals from a single loading of the desalted sample to the target. Selected sPSD spectra were used to confirm the identity of the protein using the Mascot[™] MS/MS ion search engine. The results from these searches (Figures 3-7) indicated the presence of a second protein in the 2D gel spot - Elongation Factor-Tu (EF-Tu). A review of the parent mass searches indicated that EF-Tu was also present in the search results though at a lower score. A complete analysis of the parent and sPSD spectra is summarized in Table 2 indicating that there is strong evidence for the presence of both proteins in the same 2D gel spot. Assignment of all the signals from the parent spectrum to the sequences of the two proteins indicated that 60% sequence coverage was obtained for OMP A and 30% for EF-Tu.
- 3 sPSD analysis and database searching of the 1641 Da signal (Figure 5) corresponded to a peptide, LGYPITDDLDVYTR, found in a variant of OMP A that was different from the one identified from the parent mass fingerprint. The published sequence of this variant had only one amino acid difference (F114 <-> V114) from the form identified by the peptide mass fingerprint. The equivalent peptide, LGYPITDDLDFYTR, was also observed in the parent spectrum, though not subjected to sPSD, which indicated that both forms of OMP A were present in the 2D gel protein spot.
- 4 sPSD analysis of the 1617 Da signal was useful in identifying one of two OMP A peptides of similar mass. sPSD fragmentation confirmed that the signal corresponded to OMP A 250-263 (theoretical mass MH⁺ = 1616.74) and not OMP A 46-59 (theoretical mass MH⁺ = 1617.79).
- 5 Further, sPSD analysis of the 1233 Da peak was useful in identifying one of two OMP A peptides of similar mass. sPSD fragmentation confirmed that the signal corresponded to OMP A 326-334 (theoretical mass MH⁺ = 1233.62) and not EF-Tu 118-128 (theoretical mass MH⁺ = 1233.64).
- 6 Even low intensity signals such as 1803 Da generated useful sPSD data (Figure 6) for the structural confirmation and correct protein identity.
- 7 Some signals (e.g. 1438 Da) did not correspond to peptides from any of the three proteins identified. These signals may represent post transitional modifications and will be subject to further investigation by sPSD.





Figure 2. Parent spectrum indicating signals from Outer Membrane Protein A and Elongation Factor-Tu

Figure 3. sPSD of 1264.6 Da precursor supporting the identity of Outer Membrane Protein A





Figure 4. sPSD of 2304.8 Da precursor supporting the identity of Outer Membrane Protein A

Figure 5. sPSD of 1641.8 Da precursor supporting the identity of Outer Membrane Protein A variant



Figure 6. sPSD of 1803.8 Da precursor supporting the identity of Elongation Factor-Tu

Figure 7. sPSD of 1966.2 Da precursor supporting the identity of Elongation Factor-Tu

	OMP A variant 1	OMP A variant 2	EF-Tu	
Parent spectrum				
number of peptides	10	9	8	
database position ¹	1	2	14	
sPSD ² - parent peak Da				
1027			В	
1233			В	
1264	Α			
1381		В		
1438	?	?	?	
1471	Α			
1617			В	
1641		A		
1903			Α	
1965			A	
2303		В		
2616		В		

Table 2. Summary of proteins identified from seamless PSD spectra

¹protein identified with Mascot[™] peptide mass fingerprinting search engine ²A = protein identified with Mascot[™] MS/MS ion search engine B = protein identity confirmed from the theoretical fragment comparison

Conclusions

The integration of the curved-field reflectron into a high performance MALDI TOF mass spectrometer has enabled:

- Very high sensitivity: sPSD analysis : ≤50 fmol
- Good sequence coverage for database searching
- High speed analysis: 60 to 90 sec per sPSD analysis
- Typical 8 to 10 seamless PSD spectra can be obtained from a single 0.5 µl loading of a digested Coomassie Blue stained protein and 3 to 4 from a silver stained protein
- The data obtained from sPSD provided critical support for the identification and structural characterization of proteins from 2D gels which frequently contained more than one entity

Acknowledgements

We would like thank N. Sienkiewicz²,

A. D. Cronshaw^{1,2}, F. B. Ward² and M. P. Gallagher² (The Welmet Facility¹, Institute of Cell and Molecular Biology², Biology Division, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR) for preparing the *Salmonella typhimurium* proteins by 2D gel electrophoresis and in situ trypsin digestion.

REFERENCES

1. Tanaka, K. et al; Rapid Comm. Mass Spectrom., 2, (1988), 151-3

2. Mamyrin, B.A.; USSR patent no 198,034, (1966)

3. Cotter, R.J. et al; Rapid Comm. Mass Spectrom., 8, (1994), 781-5

4. Bowdler, A. et al; ASMS Conf. Mass Spectrom. Allied Topics (1999)



www.shimadzu-biotech.net

info@shimadzu-biotech.net